TY 302
Alternative Names: TY-302Latest Information Update: 28 Oct 2024
At a glance
- Originator TYK Medicine
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Ovarian-cancer in China (Parenteral)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease) in China (PO, Capsule)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Monotherapy) in China (PO, Capsule)